Chongsheng Pharmaceutical Industry: Net profit turned from loss to profit in 2025, with a year-on-year growth of 186.91% - 203.62%.

Zhongsheng Pharmaceutical announced that the company is expected to achieve a net profit attributable to shareholders of the listed company of 260 million to 310 million yuan in 2025, achieving a turnaround from loss to profit, with a year-on-year growth of 186.91% - 203.62%; the net profit after deducting non-recurring gains and losses is expected to be 270 million to 320 million yuan, with a year-on-year growth of 203.72% - 222.93%. Basic earnings per share are expected to be between 0.31 yuan/share and 0.37 yuan/share. The performance growth is mainly due to the company's improvement in performance according to its strategic positioning, the approval for the listing of 2 innovative drugs, and the low base number in 2024 due to the provision for asset impairment losses and non-recurring gains and losses. This performance is unaudited, and specific data is subject to the annual report.